PT3793573T - Subconjuntos de células natural killer humanas que apresentam respostas imunitárias dirigidas por anticorpos melhoradas - Google Patents

Subconjuntos de células natural killer humanas que apresentam respostas imunitárias dirigidas por anticorpos melhoradas

Info

Publication number
PT3793573T
PT3793573T PT198034977T PT19803497T PT3793573T PT 3793573 T PT3793573 T PT 3793573T PT 198034977 T PT198034977 T PT 198034977T PT 19803497 T PT19803497 T PT 19803497T PT 3793573 T PT3793573 T PT 3793573T
Authority
PT
Portugal
Prior art keywords
subsets
immune responses
natural killer
killer cells
human natural
Prior art date
Application number
PT198034977T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Indapta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indapta Therapeutics Inc filed Critical Indapta Therapeutics Inc
Publication of PT3793573T publication Critical patent/PT3793573T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT198034977T 2018-05-14 2019-05-14 Subconjuntos de células natural killer humanas que apresentam respostas imunitárias dirigidas por anticorpos melhoradas PT3793573T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862671358P 2018-05-14 2018-05-14

Publications (1)

Publication Number Publication Date
PT3793573T true PT3793573T (pt) 2024-11-05

Family

ID=68541145

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198034977T PT3793573T (pt) 2018-05-14 2019-05-14 Subconjuntos de células natural killer humanas que apresentam respostas imunitárias dirigidas por anticorpos melhoradas

Country Status (10)

Country Link
US (1) US20210187025A1 (enExample)
EP (2) EP4474391A3 (enExample)
JP (2) JP2021522839A (enExample)
CN (1) CN112839666A (enExample)
AU (1) AU2019271146A1 (enExample)
CA (1) CA3099806A1 (enExample)
DK (1) DK3793573T3 (enExample)
ES (1) ES2993360T3 (enExample)
PT (1) PT3793573T (enExample)
WO (1) WO2019222293A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
KR20230088306A (ko) * 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
KR20240024048A (ko) * 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 her2 표적 항체를 이용한 암 치료 방법
AU2022254978A1 (en) 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd20 targeted antibody
KR20240024047A (ko) 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법
CN117529327A (zh) * 2021-04-08 2024-02-06 埃迪瓦生物治疗公司 用nk细胞和靶向cd20的抗体治疗肿瘤
CN117715647A (zh) * 2021-04-08 2024-03-15 埃迪瓦生物治疗公司 用nk细胞和cd38靶向抗体治疗癌症
US20240366664A1 (en) * 2021-04-08 2024-11-07 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and an egfr targeted antibody
US20240197783A1 (en) * 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
CN115521913B (zh) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK细胞与CD20、CD38、Her2抗体联合应用
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6016891A (en) 1998-08-10 2000-01-25 Sava; John G. Tree stand harness system
JP2008500832A (ja) * 2004-06-01 2008-01-17 サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法
ES2678094T3 (es) * 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
WO2009041113A1 (ja) * 2007-09-28 2009-04-02 Olympus Corporation Fc受容体遺伝子導入ＮＫ細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) * 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
AU2018219895C1 (en) * 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof

Also Published As

Publication number Publication date
CN112839666A (zh) 2021-05-25
EP3793573A1 (en) 2021-03-24
WO2019222293A1 (en) 2019-11-21
EP3793573B1 (en) 2024-10-23
EP3793573A4 (en) 2022-01-26
US20210187025A1 (en) 2021-06-24
CA3099806A1 (en) 2019-11-21
EP4474391A3 (en) 2025-02-26
AU2019271146A1 (en) 2020-12-10
JP2021522839A (ja) 2021-09-02
EP4474391A2 (en) 2024-12-11
DK3793573T3 (da) 2024-11-25
JP2024096956A (ja) 2024-07-17
ES2993360T3 (en) 2024-12-27

Similar Documents

Publication Publication Date Title
IL273979A (en) Methods for the production of adapted natural killer cells and methods of use
DK3793573T3 (da) Delmængde af humane naturlige dræberceller med forbedrede antistof-rettede immunresponser
IL269380A (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
IL269553A (en) Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
IL320844A (en) Pharmaceutical combinations for tumor treatment involving anti-CD19 antibody and natural killer cell
IL268554A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL271751A (en) T cell receptors and immunotherapy using them
IL267129A (en) New T-cell receptors and immunotherapy using them
SG11201803117YA (en) Natural killer cells and ilc3 cells and uses thereof
SG11201609118RA (en) Modified natural killer cells and uses thereof
DK3317401T3 (da) Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
SG11202007156QA (en) Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
IL285039A (en) Compositions and methods for stimulating natural killer cells
SG11202105215QA (en) Combination therapy of arms and natural killer cells
GB201704953D0 (en) Natural killer cells
IL290279A (en) Implantable structures and their use
PL3164144T3 (pl) Kompozycja Lactobacillus umożliwiająca promowanie wzrostu u młodych osobników ludzi i zwierząt w przypadku nieprawidłowego stanu odżywienia
HUE064593T2 (hu) Szilikon elasztomerek, ezek elõállítása és alkalmazása
IL276374A (en) Natural killer cells are resistant to transforming growth factor beta
GB201703476D0 (en) Natural killer cells
PL3319621T3 (pl) Kompozycje oraz sposoby modulowania i/lub stymulowania odpowiedzi immunologicznych u człowieka i/lub zwierzęcia
GB201805033D0 (en) Genetically-modified human natural killer (nk) cell
GB201805031D0 (en) Genetically-modified human natural killer (nk) cell
AU201611685S (en) Egg yolk separator
GB201705338D0 (en) Genetically-modified human natural killer (NK) cell